U.S. immuno-oncology company Harpoon Therapeutics Inc. has completed its initial public offering of 5.4 million shares of common stock at a public offering price of $14 per share.

The gross proceeds to Harpoon Therapeutics from the offering were $75.6 million, before deducting underwriting discounts and commissions and offering expenses payable by the company. 

U.S. investment banking company Citigroup and SVB Leerink, a wholly-owned subsidiary of SVB Financial Group, were the joint bookrunners on the offering.

Harpoon Therapeutics has bagged a total of $130 million in over 3 funding rounds.